Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis

Autologous haematopoietic stem cell transplantation is now well-established as an effective treatment for severe systemic sclerosis with clear demonstration of favourable end-organ and survival outcomes. Treatment-related cardiotoxicity remains the predominant safety concern and contraindicates autologous haematopoietic stem cell transplantation in patients with severe cardiopulmonary disease. In this review, we describe the cardiovascular outcomes of autologous haematopoietic stem cell transplantation recipients, discuss the potential mechanisms of cardiotoxicity and propose future mitigating strategies.

[1]  D. Ma,et al.  Successful lymphoablative autologous haematopoietic stem cell transplantation in three cases of severe autoimmune disease despite reduced dose cyclophosphamide conditioning—do we need 200 mg/kg cyclophosphamide? , 2022, Bone Marrow Transplantation.

[2]  E. Behr,et al.  Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition , 2021, Journal of scleroderma and related disorders.

[3]  OUP accepted manuscript , 2022, Rheumatology.

[4]  C. Denton,et al.  Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis , 2021, Rheumatology.

[5]  A. Vekhoff,et al.  Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation , 2021, JACC. CardioOncology.

[6]  Maria-Carolina Oliveira,et al.  Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience , 2021, Advances in Rheumatology.

[7]  E. Matteson,et al.  Increased Risk of Valvular Heart Disease in Systemic Sclerosis: An Underrecognized Cardiac Complication , 2021, The Journal of Rheumatology.

[8]  M. Nikpour,et al.  Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review. , 2020, Seminars in arthritis and rheumatism.

[9]  S. Plein,et al.  Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. , 2020, Rheumatology.

[10]  K. Sullivan,et al.  Safety and efficacy of HSCT for systemic sclerosis across clinical trials , 2020, Nature Reviews Rheumatology.

[11]  Daniel C. Lee,et al.  Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days , 2020, Bone Marrow Transplantation.

[12]  E. Nagel,et al.  CMR in Pericardial Diseases - an Update , 2020, Current Cardiovascular Imaging Reports.

[13]  E. Nagel,et al.  Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update , 2020, Journal of Cardiovascular Magnetic Resonance.

[14]  L. Kanz,et al.  Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party , 2020, Haematologica.

[15]  J. D. de Vries-Bouwstra,et al.  Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study , 2019, Annals of the Rheumatic Diseases.

[16]  WY Abdelzaher,et al.  Purine versus non-purine xanthine oxidase inhibitors against cyclophosphamide-induced cardiac and bone marrow toxicity in rats , 2020, Human & experimental toxicology.

[17]  S. Gläser,et al.  Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis , 2019, BMC Pulmonary Medicine.

[18]  M. Dweck,et al.  Myocardial fibrosis: why image, how to image and clinical implications , 2019, Heart.

[19]  M. Bikkina,et al.  Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function During Anthracycline Therapy. , 2019, The American journal of cardiology.

[20]  N. Helsby,et al.  The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes , 2019, British journal of clinical pharmacology.

[21]  Asmaa M A Bayoumi,et al.  Role of ATP-Sensitive Potassium Channel (KATP) and eNOS in Mediating the Protective Effect of Nicorandil in Cyclophosphamide-Induced Cardiotoxicity , 2019, Cardiovascular Toxicology.

[22]  G. de Luca,et al.  Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. , 2019, European journal of internal medicine.

[23]  Paul G. Williams,et al.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[24]  D. Shah,et al.  CMR in the Evaluation of Diastolic Dysfunction and Phenotyping of HFpEF: Current Role and Future Perspectives. , 2019, JACC. Cardiovascular imaging.

[25]  K. Sullivan,et al.  Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  D. Farge,et al.  Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer? , 2018, Nature Reviews Rheumatology.

[27]  H. Arheden,et al.  Decreased global myocardial perfusion at adenosine stress as a potential new biomarker for microvascular disease in systemic sclerosis: a magnetic resonance study , 2018, BMC Cardiovascular Disorders.

[28]  S. Yasuda,et al.  Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy , 2018, Modern rheumatology.

[29]  A. Risitano,et al.  Acute immune toxicity during anti‐thymocyte globulin: That's CARPA! , 2018, American journal of hematology.

[30]  C. Pepine,et al.  Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors , 2018, Cardiovascular Toxicology.

[31]  É. Mousseaux,et al.  Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening , 2017, Bone Marrow Transplantation.

[32]  T. Nishikawa,et al.  Role of metabolites of cyclophosphamide in cardiotoxicity , 2017, BMC Research Notes.

[33]  G. Kolovou,et al.  Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria , 2017, BMC Cardiovascular Disorders.

[34]  V. Hsu,et al.  Prevalence and risk factors for left ventricular diastolic dysfunction in a scleroderma cohort , 2017, Scandinavian journal of rheumatology.

[35]  Daniel C. Lee,et al.  Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners , 2017, Bone Marrow Transplantation.

[36]  C. Hill,et al.  Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme , 2017, Arthritis Research & Therapy.

[37]  C. Vitali,et al.  Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis , 2017, Bone Marrow Transplantation.

[38]  G. Kitas,et al.  Pseudo-infarction pattern in diffuse systemic sclerosis. Evaluation using cardiovascular magnetic resonance. , 2016, International journal of cardiology.

[39]  N. Fine,et al.  Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. , 2016, The Canadian journal of cardiology.

[40]  Matthias Gutberlet,et al.  Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis: The MyoRacer-Trial. , 2016, Journal of the American College of Cardiology.

[41]  K. Ohashi,et al.  The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) , 2016, Annals of Hematology.

[42]  S. Kako,et al.  Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling , 2016, International Journal of Hematology.

[43]  H. Mansour,et al.  Protective effect of N-acetylcysteine on cyclophosphamide-induced cardiotoxicity in rats. , 2015, Environmental toxicology and pharmacology.

[44]  K. Ikawa,et al.  Mechanisms of Fatal Cardiotoxicity following High-Dose Cyclophosphamide Therapy and a Method for Its Prevention , 2015, PloS one.

[45]  C. Nuñez-Alvarez,et al.  Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography. , 2015, Rheumatology.

[46]  Daniel C. Lee,et al.  Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. , 2015, JAMA.

[47]  B. Griffiths,et al.  Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. , 2014, JAMA.

[48]  L. Kanz,et al.  Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. , 2014, Rheumatology.

[49]  M. Perales,et al.  Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  C. Masciocchi,et al.  Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). , 2013, European journal of radiology.

[51]  A. Goldhirsch,et al.  Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  D. Liew,et al.  N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study , 2012, Arthritis Research & Therapy.

[53]  L. Czirják,et al.  The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. , 2012, Rheumatology.

[54]  S. Milliken,et al.  Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide , 2012, Bone Marrow Transplantation.

[55]  L. Kanz,et al.  Optimization of Autologous Stem Cell Transplantation for Systemic Sclerosis — A Single-center Longterm Experience in 26 Patients with Severe Organ Manifestations , 2012, The Journal of Rheumatology.

[56]  C. Hawkey,et al.  Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation , 2011, Bone Marrow Transplantation.

[57]  Sanjiv J Shah,et al.  Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. , 2011, Chest.

[58]  M. Labopin,et al.  Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases , 2010, Haematologica.

[59]  D. Farge,et al.  Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis , 2009, Annals of the rheumatic diseases.

[60]  N. Lamblin,et al.  Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients , 2008, Annals of the rheumatic diseases.

[61]  A. Testori,et al.  Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis , 2007, Bone Marrow Transplantation.

[62]  M. Mayes,et al.  High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. , 2007, Blood.

[63]  T. Medsger,et al.  Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. , 2007, Arthritis and rheumatism.

[64]  C. Denton,et al.  Angiographically proven coronary artery disease in scleroderma. , 2006, Rheumatology.

[65]  N. Manolios,et al.  Resolution of sclerodermatous myocarditis after autologous stem cell transplantation , 2006, Annals of the rheumatic diseases.

[66]  K. Ohta,et al.  Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone , 2005, Cancer.

[67]  P. Varalakshmi,et al.  dl-α-lipoic acid ameliorates cyclophosphamide induced cardiac mitochondrial injury , 2005 .

[68]  J. Ioannidis,et al.  Mortality in systemic sclerosis: an international meta-analysis of individual patient data. , 2005, The American journal of medicine.

[69]  M. Emdin,et al.  Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis , 2004, Bone Marrow Transplantation.

[70]  A. Troxel,et al.  Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. , 2004, Breast.

[71]  F. Breedveld,et al.  Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry , 2004, Annals of the rheumatic diseases.

[72]  K. Ohta,et al.  Predictive value of QT dispersion for acute heart failure after autologous and allogeneic hematopoietic stem cell transplantation , 2004, American journal of hematology.

[73]  Y. Nieto,et al.  Pharmacokinetics of high-dose chemotherapy , 2004, Bone Marrow Transplantation.

[74]  S. Chevret,et al.  Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I–II study , 2002, British journal of haematology.

[75]  E. Holler,et al.  The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation , 2002, Bone Marrow Transplantation.

[76]  K. Sullivan,et al.  Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease , 2001, Annals of the rheumatic diseases.

[77]  J. Al-Sadir,et al.  Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors , 2000, Bone Marrow Transplantation.

[78]  A. Freemont,et al.  Pericardial involvement in systemic sclerosis , 1997, Annals of the rheumatic diseases.

[79]  J. Gottdiener,et al.  Cardiotoxicity associated with high-dose cyclophosphamide therapy. , 1981, Archives of internal medicine.

[80]  D. Furst,et al.  The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. , 1981, Annals of internal medicine.

[81]  J. Fries,et al.  Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. , 1969, The American journal of medicine.